ReCode raises another $50M; Histogen halts clinical development; 60 Degrees withdraws Covid-19 IND
ReCode Therapeutics is back with an additional $50 million more than a year after it raised $120 million.
The Menlo Park, CA-based biotech is developing new mRNA treatments, and the key, it believes, is the delivery system. ReCode’s platform engineers lipid nanoparticles — the fatty acid capsules used in Moderna and BioNTech/Pfizer’s Covid-19 vaccines.
ReCode’s latest series B raise included two new investors: Bioluminescence Ventures and Solasta Ventures, the company said Tuesday morning. Kouki Harasaki, Bioluminescence’s founding partner and formerly of Microsoft Ventures and a16z, joined ReCode’s board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.